Europe (WHO region) vs Iceland: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Iceland
100.0%
in 2022
Europe (WHO region) rank
2nd
Iceland rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Iceland
How they compare
Iceland currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Iceland's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 4 times across 8 shared years of data; in 2005 it was Iceland ahead.
Europe (WHO region) ranks 2nd and Iceland ranks 1st of 11 groups.
Iceland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Iceland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 21.7% | 83.3% | 61.6% | Iceland |
| 2010s | 48.8% | 62.5% | 13.8% | Iceland |
| 2020s | 94.0% | 100.0% | 6.0% | Iceland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Iceland?
- Iceland, at 100.0% against 90.0% in Europe (WHO region) as of 2022.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Iceland?
- 10.0%, with Iceland ahead.
- How many years of comparable data are there for Europe (WHO region) and Iceland?
- 8 years are reported by both, from 2005 to 2022.
- How do Europe (WHO region) and Iceland rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Iceland ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.